Atom Investors LP Morphic Holding, Inc. Transaction History

Atom Investors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $522,452 - $681,468	-20,002 Reduced 23.09%	66,628 $2.27 Million
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $344,268 - $520,926	12,923 Added 17.53%	86,630 $3.05 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $551,477 - $856,933	27,643 Added 60.01%	73,707 $2.13 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $982,545 - $2.74 Million	46,064 New	46,064 $1.06 Million
Q2 2022 Aug 15, 2022	SELL	$19.74 - $43.01 $41,473 - $90,364	-2,101 Reduced 14.98%	11,925 $259,000
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $26,100 - $37,454	-720 Reduced 4.88%	14,026 $563,000
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $638,059 - $969,107	14,746 New	14,746 $699,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.